Boston Scientific Corp (BSX)vsNuwellis Inc (NUWE)
BSX
Boston Scientific Corp
$45.98
-0.13%
HEALTHCARE · Cap: $63.87B
NUWE
Nuwellis Inc
$1.89
-2.07%
HEALTHCARE · Cap: $177,950
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 234978% more annual revenue ($20.61B vs $8.77M). BSX leads profitability with a 17.3% profit margin vs -217.2%. NUWE trades at a lower P/E of 0.0x. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
NUWE
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-23.2%
Fair Value
$37.36
Current Price
$45.98
$8.62 premium
Intrinsic value data unavailable for NUWE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 26.2% year-over-year
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -657.5% — below average capital efficiency
Earnings declined 99.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : NUWE
The strongest argument for NUWE centers on P/E Ratio, Price/Book, Debt/Equity. Revenue growth of 26.2% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : NUWE
The primary concerns for NUWE are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
BSX profiles as a mature stock while NUWE is a growth play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.58 — expect wider price swings.
NUWE is growing revenue faster at 26.2% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 37/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Nuwellis Inc
HEALTHCARE · MEDICAL DEVICES · USA
Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?